|
注册号: Registration number: |
ChiCTR1800016065 |
|
最近更新日期: Date of Last Refreshed on: |
2018-05-09 17:34:12 |
|
注册时间: Date of Registration: |
2018-05-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
血必净对重症患者膈肌功能的影响 |
|
Public title: |
Effect of Xuebijing infusion on diaphragmatic function in critical ill patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
血必净对重症患者膈肌功能的影响 |
|
Scientific title: |
Effect of Xuebijing infusion on diaphragmatic function in critical ill patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
于涛 |
研究负责人: |
于涛 |
|
Applicant: |
Tao YU |
Study leader: |
Tao YU |
|
申请注册联系人电话: Applicant telephone: |
+86 18855392038 |
研究负责人电话:
Study leader's |
+86 18855392038 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yutao197808@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yutao197808@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽芜湖市赭山西路2号 |
研究负责人通讯地址: |
安徽芜湖市赭山西路2号 |
|
Applicant address: |
2 Zheshan Road West, Wuhu, Anhui, China |
Study leader's address: |
2 Zheshan Road West, Wuhu, Anhui, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
皖南医学院弋矶山医院 |
||
|
Applicant's institution: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital |
||
|
研究负责人所在单位: |
皖南医学院弋矶山医院 |
||
|
Affiliation of the Leader: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2018-04 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
皖南医学院弋矶山医院 |
||
|
Name of the ethic committee: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
曹衡 |
||
|
Contact Name of the ethic committee: |
Heng CAO |
||
|
伦理委员会联系地址: |
皖南医学院弋矶山医院 |
||
|
Contact Address of the ethic committee: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital, 2 Zheshan Road West, Wuhu, Anhui, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
皖南医学院弋矶山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽芜湖市赭山西路2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Zheshan Road West, Wuhu, Anhui, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
皖南医学院弋矶山医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Wannan Medical College First Affiliated Hospital, Yijishan Hospital |
||||||||||||||||||||||
|
研究疾病: |
感染 |
||||||||||||||||||||||
|
Target disease: |
sepsis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨血必净对重症患者膈肌功能的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the effect of Xuebijing infusion on diaphragmatic function in critical ill patients |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
明确诊断Sepsis 的时间超过 48小时;孕妇、哺乳期妇女;体重指数<18.5,或>30;影响生存的严重原发性疾病;肝或肾单项SOFA 评分≥3分;近6个月内持续使用免疫抑制剂,或器官移植者;入组前7天连续使用过激素,换算为甲强龙剂量≥20mg/天者;30天内参加过其他临床试验者;研究者判断不能完成或不宜参加本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
The time for the diagnosis of Sepsis was more than 48 hours; pregnant women, lactation women, body mass index <18.5, or >30; the severe primary disease affecting survival; the single SOFA score of the liver or kidney was more than 3; in the last 6 months, the use of immunosuppressive agents, or organ transplant recipients, continued to use hormone and converted tomore than 20mg/ days methylprednisolone on the first 7 days of the group. Those who had participated in other clinical trials within 30 days; the researchers judged that they could not complete or should not participate in the study |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2018-05-01 00:00:00至 To 2019-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2018-05-01 00:00:00 至 To 2019-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
用第三方中央随机化系统(IWRS) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
interactive web response system |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2020.6 http://www.chictr.org.cn/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2020.6 http://www.chictr.org.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Case Record Form, CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |